XERMELO (Ipsen Pty Ltd)
Product name
XERMELO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
219 working days (255)
Active ingredients
telotristat etiprate
Registration type
NCE/NBE
Indication
XERMELO (film coated tablets) is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.